Table 1

Clinicopathological characteristics of high podocalyxin-expressing tumors

Tumor histologyTumor sizeLymph node metastasisTumor grade
High podocalyxin group 3; n = 15 (6%)IDC-13 (87%); ILC-1 (7%); medullary-1 (7%)≤20 mm-6 (40%); >20 mm-7 (46.6%); unknown-2 (13.4%)Present-3 (20%); absent-9 (60%); unknown-3 (20%)I-none; II-6 (40%); III-9 (60%)
Low or no podocalyxin groups 0, 1, 2; n = 257 (94%)IDC-214 (83%) ILC-25 (10%) mucinous-6 (2%), other-12 (5%)<20 mm-122 (47.6%); >20 mm-94 (36.6%); unknown-20 (7.8%)Present-77 (30%); absent-151 (59%); unknown-29 (11%)I-54 (21%); II-141 (55%); III-62 (24%)
Significance (P)NS *NS *NS *0.001 *
ER statusP53 stainingHer-2 stainingVital status
Positive-5 (33%); negative-9 (60%); unknown-1 (7%)Positive-5 (33%); negative-8 (53%); unknown-2 (13%)Strong-2 (13%); weak/neg-13 (87%)Breast cancer death-8 (53%); other cause death-3 (20%); alive-4 (29%)
Positive-167 (65%); negative-61 (23.7%); unknown-29 (11.3%)Positive-29 (11%); negative-194 (75);% unknown-24 (9%)Strong-22 (9%); weak/neg-225 (88%); unknown-10 (4%)Breast cancer death-69 (27%); other cause death-58 (22.6%); alive-130 (50.6%)
0.003*0.01*NS*0.01
  • NOTE. Detailed clinico-pathological characteristics of a subset of tumors with high level of Podocalyxin expression compared to the remainder of the cases (low or no Podocalyxin groups) on the invasive breast tumor microarray.

  • Abbreviations: IDC, infiltrative ductal carcinoma (not otherwise specified category); ILC, infiltrative lobular carcinoma; NS, non-significant (P > 0.05).

  • * Spearman’s non-parametric test was used.

  • Log-rank test, disease specific survival.